Barclays
AARD

Barclays’s Aardvark Therapeutics AARD Stock Holding History

Barclays’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Sell
2,259
-1,362
-38% -$6.36K ﹤0.01% 4666
2026
Q1 		$13.7K Sell
3,621
-16,895
-82% -$175K ﹤0.01% 4652
2025
Q4 		$269K Sell
20,516
-19,410
-49% -$242K ﹤0.01% 4170
2025
Q3 		$531K Sell
39,926
-10,632
-21% -$120K ﹤0.01% 3771
2025
Q2 		$684K Buy
+50,558
New +$521K ﹤0.01% 3577

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Barclays's AARD Position: Q2 2026 in Review

Barclays reduced its Aardvark Therapeutics (AARD) stake by 38% in Q2 2026, selling an estimated $6.36K and leaving 2,259 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #4666.

Barclays first reported a position in AARD in Q2 2025 and has held it in 5 quarters since. The position peaked at $684K in Q2 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Barclays held 2,259 shares of Aardvark Therapeutics worth $13K as of Q2 2026.
  • Barclays sold 1,362 Aardvark Therapeutics shares in Q2 2026, an estimated $6.36K.
  • Aardvark Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4666 holding.
  • Barclays first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Barclays's Aardvark Therapeutics position peaked at $684K in Q2 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.